The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma. by Begent, R. H. et al.
Br.J.Cacer(198),55, 65 660 © Te Macmilln Press td., 198
The clinical value of imaging with antibody to human chorionic
gonadotrophin in the detection of residual choriocarcinoma
R.H.J. Begent, K.D. Bagshawe, A.J. Green and F. Searle
Cancer Research Campaign Laboratories, Charing Cross and Westminster Medical School, Charing Cross Hospital,
London W6 8RF, UK.
Summary Choriocarcinoma can be imaged by external scintigraphy after intravenous administration of
radiolabelled antibody directed against human chorionic gonadotrophin (HCG). The purpose of this study
was to investigate whether antibody imaging was sufficiently sensitive and specific to improve the selection of
patients for surgical resection of localised deposits of drug resistant or recurrent choriocarcinoma. Eighteen
patients with raised serum HCG concentrations in whom the site of tumour was not known were investigated
by antibody imaging and conventional imaging methods. When the tumour appeared localised, resection was
attempted. Tumour was found at all sites in which both antibody imaging and conventional imaging methods
were positive. Antibody imaging gave false positive results in 2 of 18 patients and false negatives in 5.
Computerised tomography was false positive in one case and false negative in 2. In these patients, antibody
imaging gave true negative and true positive results respectively. Of 8 patients with positive antibody imaging
in whom resection was attempted, 5 achieved sustained complete response with up to five years follow up. It
is concluded that antibody imaging is useful in selection of patients for surgery in drug resistant or recurrent
choriocarcinoma.
Although the majority of patients with choriocarcinoma are
curable with chemotherapy, drug resistant tumour is still the
major cause of death (Begent & Bagshawe, 1982). Some of
these patients have localised disease which can be cured by
surgical resection, usually combined with adjuvant chemo-
therapy. Success of this strategy depends on accurate local-
isation of the tumour and on discrimination between viable
tumour masses and the residual non-viable masses often
found at sites from which choriocarcinoma has been eradi-
cated. The presence of drug resistant choriocarcinoma is
demonstrable by measurement of serum human chorionic
gonadotrophin (HCG) concentrations. The sensitivity of this
test exceeds that of any present imaging method so that
patients with drug resistant choriocarcinoma are seen with
rising serum HCG values but no clear indication of the site
of active tumour.
Antibody imaging, in which tumours are imaged by
external scintigraphy after intravenous injection of radio-
labelled antibody directed against HCG provides a way of
locating these tumours and demonstrating HCG production
at the site concerned. Earlier studies of antibody imaging
have shown that large deposits of choriocarcinoma can be
located and that the sensitivity was sometimes sufficient to
make the investigation useful in clinical decision making
(Begent et al., 1980; Goldenberg et al., 1980, 1981).
This paper describes a study in which antibody imaging
was performed in patients with drug resistant or recurrent
choriocarcinoma in whom there was a rise in serum HCG
values but the site of tumour was not known. The results
were compared with those of conventional imaging methods
and assessed for their value in selection of patients for
surgery.
Materials and methods
Antibodies
The details of the antibodies directed against HCG, their
purification and radiolabelling have been described
previously (Searle et al., 1984; Begent et al., 1980). Briefly, a
mouse monoclonal (W14A) and a sheep antibody to HCG
were purified by binding to a column of HCG linked to
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Sepharose CL 4B and eluted with ammonium thiocyanate.
They were labelled with 131-Iodine (1311) by the chloramine
T method and aggregates removed by gel filtration.
Administration to patients
The thyroid was blocked with potassium iodide 60mg tds for
10 days, starting 24h before administration of antibody.
Potassium perchlorate 200mg 6 hourly was given 4 doses
after antibody administration. One hundred to 500,ug
antibody labelled with 0.6-1.6mCi 1311 was given i.v. after
negative intradermal testing for immediate type hyper-
sensitivity with 10pg antibody.
Imaging
Background radioactivity in normal tissues was simulated by
giving 99mTechmetium (99mTc) labelled albumin and 99mTc04
45min before imaging. Images of 1311 labelled antibody and
99mTc subtraction medium were obtained 24h after antibody
administration using a Nuclear Enterprises LFOV gamma
camera linked to a Nodecrest computer. The 99mTc image
was subtracted from that of 1311 antibody to identify areas
of specific antibody uptake as described by Goldenberg et al.
(1978). Numerical analysis of areas of relative accumulation
of 1311 antibody on the subtraction image was performed by
the method of Green et al. (1984). In brief, regions of
interest were drawn around the suspect area and around an
apparently normal area in the same organ or tissue. The
ratio of counts of 1311 in the two regions was compared with
that of 99mTc in the same regions. The difference between the
two ratios was expressed in terms of standard deviations
known as an Fx value. Areas known to produce artefacts in
subtraction imaging such as the urinary bladder, heart and
lower border of the liver (Begent, 1985) were excluded from
analysis.
Results
Eighteen patients with drug resistant or recurrent chorio-
carcinoma in whom the site of tumour was not known were
studied. In nine patients the antibody was of sheep and in
nine of mouse monoclonal origin. No difference was seen
between the images with the two reagents. Numerical
analysis of images was performed by the method of Green et
al. (1984) in 12 of these. The remaining 6 patients were
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studied before this method was devised and the data were
acquired in a form which was not analysable. The results of
the numerical analysis are shown in Figure 1. Sites at which
tumour was later found tended to have higher Fx values
than other sites at which no tumour was found. If an Fx
value of +4 or greater is considered positive this gives a
predictive value of a positive:
True+ve 9
True+ve+false+ve o 1
Table I Antibody imaging and selection of patients with chorio-
carcinoma for surgery
Number ofsites
Site True positive False positive False negative
Lung 6 - 3
Brain 2 - -
Pelvis 2 - 2
Other abdominal 1 2
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Figure 1 Numerical analysis of antibody imaging in patients
with choriocarcinoma. Fx values are for sites which were suspect
on visual examination of subtraction images and for apparently
normal areas for each patient. A mean of 8.5 areas was studied
in each patient. Results have been separated according to
whether tumour was subsequently found at the indicated site.
tumour. Eight of these had positive antibody imaging at the
site concerned. The other 3 were operated on when antibody
imaging was negative because of positive CT or ultrasound.
The relationship of antibody imaging to the histological
findings in the resected tissue is shown in Table II. Of the 3
patients who had negative antibody imaging viable tumour
was found in 2 but only necrotic tisue in the third. Two of
the patients who had tumour resected had positive antibody
imaging when other investigations gave false negative results.
The tumours were pulmonary and uterine respectively.
Table II Comparison of antibody imaging and surgical findings in
patients with choriocarcinoma
Antibody imaging result
True False True False
Site Resections positive positive negative negative
Lung 9 6 2 1
Brain I 1 - -
Pelvis 1 I
Antibody imaging gave true-positive results in two cases in which
other methods produced false-negative results.
The value of surgery to such patients depends on whether
they attain a sustained complete remission. Five of the eight
patients with positive antibody imaging whose tumours were
resected achieved this as shown in Table III. Figure 2 shows
an example of antibody imaging in which the tumour was
located and resected leading to complete response. Figure 3
shows the effect of resection of choriocarcinoma in another
patient where all other means of imaging had failed to locate
the tumour.
The higher the Fx value, the greater was the probability
that the result was a true positive. It should also be noted
that 50% of tumour sites gave false negative results.
Interpretation of the earlier studies which could not be
analysed by the Fx method was done subjectively using the
experience gained from the Fx studies.
The results of antibody imaging were compared with the
findings of computerised tomography (CT), ultrasound and
subsequent surgery. The results are shown in Table I and
indicate the value of antibody imaging in selection of
patients for surgery. Serum HCG concentrations ranged
from 18 to 358,096iul-1 (median 321). Antibody imaging
was negative in the patient with a value of 18 iu 1- 1 but
positive in 2 patients with values between 20 and 30 iul-1.
Although the value of 358,096iu 1- might have been
expected to be associated with complexing of antibody to
HCG in the circulation, this did not prevent tumour
localisation.
After antibody imaging and other investigations 11
ptatients were judged suitable for surgical resection of
Table III Effect of surgery in patients with chorio-
carcinoma with positive antibody imaging
Site Sustained complete response Early relapse
Lung 5 1
Brain 0 1
Pelvis 0 1
Discussion
Previous studies have shown that antibody imaging with
antibody directed against HCG can locate deposits of
choriocarcinoma (Begent et al., 1980; Goldenberg et al.,
1980, 1981; Searle et al., 1984). This study shows that the
method has a sensitivity and specificity which make it useful
in clinical management.
The clinical situation chosen in which to try to locate
tumour is a demanding one because measurements of serum
HCG concentration give a very sensitive indication of the
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Figure 2 Antibody imaging in a patient with recurrent chorio-
carcinoma. Anterior gamma camera views of the thorax and
upper abdomen 24h after administration of W14 mouse mono-
clonal antibody to HCG show (a) Image of 131I labelled
antibody with activity principally in the heart (H). (b) Image of
99M"Tc subtraction medium. (c) After subtraction of (b) from (a),
residual activity can be seen in the lower part of the left thorax
(T). The Fx value for this area was +4.3. The regions of interest
drawn over the right lung in each image are those used for
calculation of the Fx value for an apparently normal area and
gave an Fx value of -0.6.
A hydatidiform mole was evacuated from the uterus 46
months before antibody imaging. After initially falling to normal,
HCG values rose but returned to normal after methotrexate
therapy. Later, HCG values rose once more and failed to fall in
spite of intensive chemotherapy with methotrexate, actinomycin
D, etoposide, vincristine and cyclophosphamide. CT showed an
equivocally abnormal area in the lower lobe of the left lung
corresponding to the abnormal area on antibody imaging. Serum
HCG was 25iul-1. On the basis of the antibody imaging and
CT results, thoracotomy was performed. A 1 cm nodule was
found in the left lower lobe and resected. Histology showed
viable choriocarcinoma. Serum HCG fell to normal after 8 days
and the patient remained in complete remission, later having
adjuvant chemotherapy.
presence of choriocarcinoma. The tumours resected from
patients in this study often contained only microscopic areas
of viable tumour. Necrotic areas are a characteristic feature
of choriocarcinoma, particularly if chemotherapy has been
given, and formed the greater part of several of the tumours
excised. This explains why deposits of choriocarcinoma can
sometimes be imaged by CT when serum HCG levels are
only modestly raised. Since antibody imaging is presumed to
depend on the presence of viable choriocarcinoma, it is
remarkable that tumour could often be located by antibody
imaging when serum HCG concentrations were less than
1,000iu 1- 1 and occasionally when they were below
100 iul-1.
Nevertheless, antibody imaging needs to be reliable in
patients with very small deposits of tumour if it is to indicate
the site of viable tumour and whether an attempt at re-
section is reasonable. The finding that tumour could some-
times be located when CT and ultrasound failed and that
patients subsequently benefitted from the resulting tumour
resection shows that antibody imaging has a place in the
management of drug resistant or recurrent choriocarcinoma.
The potential of antibody imaging for discriminating
between viable and necrotic tumour is illustrated by one
patient who had positive CT but negative antibody imaging.
When resected, the lesion was found to contain only necrotic
tissue. The use of antibody imaging in this role is limited by
its sensitivity so that, in practice, it is not possible to tell
Figure 3 Serum HCG values in a patient with drug-resistant
choriocarcinoma. The rising HCG values in spite of chemo-
therapy (CHAMOCA=cyclophosphamide, hydroxyurea, actino-
mycin D, methotrexate, vincristine, citrovorum factor and adria-
mycin; VBL=vinblastine; Adria=adriamycin; VP=etoposide;
Ad=actinomycin D; MTX=methotrexate; VCR=vincristine)
show the ineffectiveness of therapy. A laparotomy was per-
formed in search of potentially resectable tumour but none was
found. Antibody imaging showed evidence of specific uptake in
the left lung. CT showed a bullus and changes consistent with
long standing fibrosis but no features characteristic of tumour. A
left pneumonectomy was performed on the basis of the antibody
imaging and HCG levels fell as shown. Adjuvanrt chemotherapy
was given and the patient remains tumour free 6 years later.
whether negative antibody imaging with positive CT means
that there is no viable tumour or merely that there is too
little to be detected by antibody imaging. To a considerable
extent antibody imaging and other imaging methods are
complementary. All of the patients in this study who had
positive antibody imaging and CT or ultrasound had viable
tumour at the site concerned. When only one investigation
was positive there were false positives and false negatives on
each side.
Antibody imaging can be difficult to interpret, particularly
when small tumours are being sought. The Fx method
(Green et al., 1984) has done much to resolve this problem
by providing an objective means of interpretation and giving
the result in numerical terms so that the probability of a
result being correct can be calculated.
There are other ways in which antibody imaging may be
improved such as by use of IIt-Indium labelled antibodies
(Rainsbury et al., 1983; Fairweather et al., 1983; Buckley &
Searle, 1984), 123-Iodine labelled antibodies F(ab) fragments
(Mach et al., 1980; Buchegger et al., 1983; Chatal et al.,
1984; Larson et al., 1983) and second antibody (Begent et
al., 1982). These topics and the relative merits of monoclonal
and polyclonal antibodies have been discussed previously
(Begent, 1985). As antibody imaging develops so other
imaging methods are also likely to advance and the selection
ofpatients for surgery to improve further.
The proportion of patients with choriocarcinoma whose
disease is not eradicated by chemotherapy is small but some
of these can be cured by the additional use of surgery
(Begent & Bagshawe, 1982). Antibody imaging makes a
valuable contribution by enhancing our ability to locate
viable tumour and improving selection for surgery.
We are grateful to Mr G. Rawlins and his team for antibody
production and to Mrs T.A. Adam for immunoaffinity purification
of antibodies. We would also like to thank the gynaecologists,
physicians and surgeons who referred patients and assisted in their
management. This work was supported by the Cancer Research
Campaign and the Medical Research Council.660 R.H.J. BEGENT et al.
References
BEGENT, R.H.J. (1985). Recent advances in tumour imaging. Use of
radiolabelled antitumour antibodies. Biochim. Biophys. Acta, 780,
151.
BEGENT, R.H.J. & BAGSHAWE, K.D. (1982). The management of
high-risk choriocarcinoma. Semin. Oncol., 9, 198.
BEGENT, R.H.J., KEEP, P.A., GREEN, A.J. & 6 others (1982).
Liposomally entrapped second antibody improves tumour
imaging with radiolabelled (first) antitumour antibody. Lancet, ii,
739.
BEGENT, R.H.J., SEARLE, F., STANWAY, G. & 4 others (1980).
Radioimmunolocalization of tumours by external scintigraphy
after administration of 1311 antibody to human chorionic
gonadotrophin: Preliminary communication. J. R. Soc. Med., 73,
624.
BUCHEGGER, F., HASKELL, C.M., SCHREYER, M. & 4 others (1983).
Radiolabelled fragments of monoclonal antibodies against
carcinoembryonic antigen for localization of human colon
carcinoma grafted into nude mice. J. Exp. Med., 158, 413.
BUCKLEY, R.G., SEARLE, F. (1984). An efficient method for
labelling antibodies with [I"IIn]. FEBS Lett., 166, 202.
CHATAL, J.-F., SACCAVINI, J.-C., FUMOLEAU, P. & 5 others (1984).
Immunoscintigraphy of colon carcinoma. J. Nucl. Med., 25, 307.
FAIRWEATHER, D.S., BRADWELL, A.R., DYKES, P.W. & 4 others
(1983). Improved tumour localisation using Indium-111 labelled
antibodies. Br. Med. J., 287, 167.
GOLDENBERG, D.M., KIM, E.E. & DELAND, F.H. (1981). Human
chorionic gonadotrophin radioantibodies in the radioimmuno-
detection of cancer and for the disclosure of occult metastases.
Proc. Natl Acad. Sci. USA, 78, 7754.
GOLDENBERG, D.M., DELAND, F., KIM, E. & 6 others (1978). Use
of radiolabelled antibodies to carcinoembryonic antigen for the
detection and localization of diverse cancers by external
photoscanning. N. Engl. J. Med., 298, 1384.
GOLDENBERG, D.M., KIM, E.E., DELAND, F.H., VAN NAGELL, JR.,
J.R. & JAVADPOUR, N. (1980). Clinical radioimmunodetection of
cancer with radioactive antibodies to human chorionic gonado-
trophin. Science, 208, 1284.
GREEN, A.J., BEGENT, R.H.J., KEEP, P.A. & BAGSHAWE, K.D.
(1984). Analysis of radioimmunodetection of tumours by the
subtraction technique. J. Nucl. Med., 25, 96.
LARSON, S.M., BROWN, J.P., WRIGHT, P.W., CARRASQUILLO, A.,
HELLSTROM, I. & HELLSTROM, K.E. (1983). Imaging of
melanoma with 1_131 labelled monoclonal antibodies. J. Nucl.
Med., 24, 123.
MACH, J.-P., FORNI, M., RITSCHARD, J. & 5 others (1980). Use of
limitations of radiolabeled anti-CEA antibodies and their
fragments for photoscanning detection of human colorectal
carcinomas. Oncodev. Biol. Med., 1, 49.
RAINSBURY, R.M., OTT, R.J., WESTWOOD, J.H. & 5 others (1983).
Location of metastatic breast carcinoma by a monoclonal
antibody chelate labelled with Indium-l 1. Lancet, ii, 934.
SEARLE, F., PARTRIDGE, C.S., KARDANA, A. & 4 others (1984).
Preparation and properties of a mouse monoclonal antibody
(W14A) to human chorionic gonadotrophin. Int. J. Cancer, 33,
429.